<?xml version="1.0" encoding="UTF-8"?>
<p>On June 15, 2020, the U.S. Food and Drug Administration (FDA) revoked the emergency use authorization granted on March 28, 2020 for chloroquine phosphate and hydroxychloroquine sulfate in certain hospitalized COVID-19 patients. They cite the serious cardiac adverse events and other protentional serious side effects to outweigh the potential benefits of their use (
 <xref rid="B94" ref-type="bibr">94</xref>).
</p>
